Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

NCT03846583 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study halted prematurely, prior to enrollment of first participant.

Conditions

Breast Cancer

Interventions

DRUG: Tucatinib
DRUG: Abemaciclib
DRUG: Trastuzumab
DRUG: Aromatase Inhibitor

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]